While all three drug classes similarly reduced the risk of major adverse cardiovascular events, only SGLT2 inhibitors significantly lowered the cardiovascular death risk, underscoring their superior benefits for renal and heart failure outcomes over Finerenone and GLP-1 RAs [36]. This evidence concerns the gene GLP1R and heart failure.